form8-k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 19, 2007

Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)

Delaware
000-50679
77-0487658
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

149 Commonwealth Drive
Menlo Park, CA  94025
(Address of principal executive offices, with zip code)

(650) 327-3270
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 8.01
Other Events.

On March 19, 2007 Corcept Therapeutics Incorporated issued a press release announcing that Study 06, the last of three Phase 3 trials evaluating CORLUX® for treating the psychotic features of Psychotic Major Depression, did not achieve statistical significance with respect to its primary endpoint.
 
Item 9.01
Financial Statements and Exhibits.

Exhibit 99.1 Press Release dated March 19, 2007

              
-2-

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
CORCEPT THERAPEUTICS INCORPORATED
   
   
Date:  March 23, 2007
By:
/s/ Fred Kurland
 
 
 Fred Kurland
 
 
 Chief Financial Officer

             
-3-
 
Exhibit Index
 
Exhibit No.
  
Description
 
    
 
Study 06 Results
 
 
-4-